Smith & Nephew Plc Additional Annual General Meeting update (1106U)
March 31 2021 - 04:00AM
UK Regulatory
TIDMSN.
RNS Number : 1106U
Smith & Nephew Plc
31 March 2021
Smith+Nephew Additional Annual General Meeting update
31 March 2021
Further to the Notice of Annual General Meeting ("2021 Notice of
Meeting") published on 1 March 2021, Smith+Nephew (LSE:SN,
NYSE:SNN), the global medical technology business, confirms the
following in respect of the format of its Annual General Meeting
("AGM") to be held at 4:00 pm on Wednesday, 14 April 2021.
The Government's updated COVID-19 guidance, issued on 29 March
2021, reiterated that restrictions remain in place across the
country preventing individuals from different households mixing
indoors and requesting that people 'minimise travel'. Shareholders
are therefore reminded they must not physically attend the AGM, in
line with the Government's measures and restrictions that will be
in force at the date of the AGM.
The AGM will be conducted as a hybrid meeting, enabling
shareholders to attend and participate (voting and raising
questions) by electronic means. A free phone telephone facility is
also available to shareholders who may not have access to a
Computer and wish to listen to the meeting and raise questions by
telephone. Further information on how shareholders can join the
hybrid meeting electronically via an online meeting platform,
submit questions and vote can be found on pages 17-19 of our 2021
Notice of Meeting. Please be reminded that shareholders will
require their SRN and PIN to access the meeting electronically.
These can be found printed on your Form of Proxy or in your email
notification, if you have chosen to receive shareholder
communications electronically. The physical meeting will only be
attended by the Chair, Chief Financial Officer and the Company
Secretary, with all other Directors attending electronically.
The hybrid AGM will commence at 4:00 pm on Wednesday, 14 April
2021 but shareholders should note that electronic entry to the
meeting via the online meeting platform will open at 3:30 pm.
Enquiries
Investors/ Analysts
Andrew Swift +44 (0) 1923 477433
Smith+Nephew
Media
Charles Reynolds +44 (0) 1923 477314
Smith+Nephew
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business that
exists to restore people's bodies and their self-belief by using
technology to take the limits off living. We call this purpose
'Life Unlimited'. Our 18,000 employees deliver this mission every
day, making a difference to patients' lives through the excellence
of our product portfolio, and the invention and application of new
technologies across our three global franchises of Orthopaedics,
Advanced Wound Management and Sports Medicine & ENT. Founded in
Hull, UK, in 1856, we now operate in more than 100 countries, and
generated annual sales of $4.6 billion in 2020. Smith+Nephew is a
constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group'
and 'Smith+Nephew' are used to refer to Smith & Nephew plc and
its consolidated subsidiaries, unless the context requires
otherwise.
For more information about Smith+Nephew, please visit
www.smith-nephew.com and follow us on Twitter , LinkedIn ,
Instagram or Facebook .
Forward-looking Statements
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading margins, market trends and our product
pipeline are forward-looking statements. Phrases such as "aim",
"plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith+Nephew, these factors include: risks
related to the impact of COVID-19, such as the depth and longevity
of its impact, government actions and other restrictive measures
taken in response, material delays and cancellations of elective
procedures, reduced procedure capacity at medical facilities,
restricted access for sales representatives to medical facilities,
or our ability to execute business continuity plans as a result of
COVID-19; economic and financial conditions in the markets we
serve, especially those affecting health care providers, payers and
customers (including, without limitation, as a result of COVID-19);
price levels for established and innovative medical devices;
developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers
(including, without limitation, as a result of COVID-19);
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that
Smith+Nephew has filed with the U.S. Securities and Exchange
Commission under the U.S. Securities Exchange Act of 1934, as
amended, including Smith+Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith+Nephew as of the date of the statement. All written or oral
forward-looking statements attributable to Smith+Nephew are
qualified by this caution. Smith+Nephew does not undertake any
obligation to update or revise any forward-looking statement to
reflect any change in circumstances or in Smith+Nephew's
expectations.
Trademark of Smith+Nephew. Certain marks registered US Patent
and Trademark Office.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
FURWPUQAWUPGURG
(END) Dow Jones Newswires
March 31, 2021 05:00 ET (09:00 GMT)
Smith & Nephew (LSE:SN.)
Historical Stock Chart
From Feb 2024 to Mar 2024
Smith & Nephew (LSE:SN.)
Historical Stock Chart
From Mar 2023 to Mar 2024